Forty patients scheduled for MP-TLT by their ophthalmologist will be recruited. Patients will be randomized to receive either topical anesthesia with 2% lidocaine gel or a sub-tenon injection with 2 ml of 1% lidocaine, in addition to tetracaine drops. One eye per patient is included, based on randomization, even if both are treated.~MP-TLT will be performed according to the current recommendations for both groups.~Baseline IOP will be calculated as the mean of three separate measurements taken on different days preoperatively. IOP will then be measured 1 week, 1 month, 3 months, 6 months and 12 months after MP-TLT.~The central corneal thickness (CCT), the central retinal thickness (CRT), anterior chamber flare and the visual field (HFA 24-2 faster) will also be measured preoperatively and during follow up.~In accordance with the World Glaucoma Association guidelines, no adjustment for multiple comparisons is planned in this study.
Micro pulse transscleral laser treatment (MP-TLT) is a relatively new method to reduce the intraocular pressure (IOP) in glaucoma. New recommendations regarding the treatment protocol has recently been developed and was published 2022.~The overall objective is to evaluate the efficacy and safety of the proposed treatment method in an independent study. In addition, the outcome of MP-TLT in patients with pseudoexfoliation glaucoma, which is relatively common in the Nordic countries, and primary open angle glaucoma will be studied separately. Furthermore, the study will evaluate the effectiveness of two alternate methods of anesthesia before MP-TLT. Patients will be randomized to receive either sub-tenon anesthesia with lidocaine injection or topical anesthesia with lidocaine gel.~The IOP change over the course of one year will be monitored, as well as success rate and survival. Further, patient-reported discomfort from the treatment and the occurrence of any adverse events or complications will be studied.